ACHIEVE LIFE SCIENCES, INC. — Director's Dealing 2017

Jun 14, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ONCOGENEX PHARMACEUTICALS, INC. (OGXI)
CIK: 0000949858
Period of Report: 2017-06-12

Reporting Person: Cormack Scott Daniel (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-06-12	Common Stock	M	9375	$0.00	Acquired	149425	Direct
2017-06-12	Common Stock	F	4472	$0.36	Disposed	144953	Direct
2017-06-12	Common Stock	M	5000	$0.00	Acquired	89055	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-06-12	Restricted Stock Unit (RSU)	$	M	9375	Disposed	2018-06-12	Common Stock (9375)	Direct
2017-06-12	Restricted Stock Unit (RSU)	$	M	5000	Disposed	2018-06-12	Common Stock (5000)	Indirect

Footnotes

F1: Represents shares of common stock acquired upon settlement of the restricted stock units ("RSUs") listed in Table II.

F2: Represents shares of common stock that have been withheld by the issuer to satisfy the tax liability in connection with the settlement of RSUs and does not represent a sale by the reporting person.

F3: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock at settlement.

F4: Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually each anniversary of June 12, 2014, subject to the reporting person's provision of service to the issuer on each vesting date.